Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06292117 · ClinicalTrials.gov registry record
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
A clinical trial of Ischemic Stroke and CYP2C19 Polymorphism, sponsored by University of Virginia.
- Recruiting
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT06292117 is a study of Ischemic Stroke and CYP2C19 Polymorphism that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 350 participants, below the 1,458-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06292117, a study of Ischemic Stroke and CYP2C19 Polymorphism, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood thinners to prevent it from happening again. One of these blood thinners, called clopidogrel, is less effective in some people due to differences in their DNA. Clopidogrel needs to be activated by a specific enzyme in the body known as CYP2C19. This enzyme does not work as well if there are variations in the section of DNA that tells the body how to make CYP2C19. It can be predicted who has less CYP2C19 enzyme activity with a genetic test. If these patients are given a different blood thinner, it can reduce their risk of another stroke compared to if they are given clopidogrel. The main questions this study aims to answer are: * What are the best strategies to implement this genetic test in the hospital? * Does implementation of this genetic test change providers' decisions on which medication to prescribe after a participant has a stroke? Participants in this study will have a genetic test done onsite looking for variations in the section of DNA that tells the body how to make CYP2C19. This genetic test will only look for 11 known variations; the genome will not be sequenced. The investigators will alert the doctor of the patient's test results so they can prescribe the appropriate blood thinner. Through this, the investigators will learn the best practices for successful implementation of this genetic test.
Conditions Studied
Interventions
- OTHER CYP2C19 Genotype
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06292117
The ClinicalTrials.gov registry entry for NCT06292117 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,458-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (76% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which CYP2C19 Genotype is the first listed.
NCT06292117 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06292117 about?
NCT06292117 is a clinical study titled "Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke". The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood...
What is the current status of trial NCT06292117?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-04-16. Estimated completion is 2026-06.
What conditions does trial NCT06292117 study?
This clinical trial studies the following conditions: Ischemic Stroke, CYP2C19 Polymorphism.
What interventions are being tested in trial NCT06292117?
The interventions under investigation include: CYP2C19 Genotype (OTHER).
Who is sponsoring clinical trial NCT06292117?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06292117 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Transitions of Care for Stroke Patients
RECRUITING
-
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
RECRUITING · NA
-
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.